Press Releases
Feb 27, 2019
Summary ToggleIntellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission Engineered cell therapy platform will enable wholly owned development candidate for acute
Jan 24, 2019
Summary ToggleIntellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed Fred Cohen , M.D., D.Phil, F.A.C.P., to its board of
Dec 6, 2018
Summary ToggleIntellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing
Nov 8, 2018
Summary ToggleIntellia Therapeutics to Present at November Healthcare Investor Conferences
CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
Oct 31, 2018
Summary ToggleIntellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its lead transthyretin
Oct 30, 2018
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2018 Earnings and Corporate Developments
CAMBRIDGE, Mass. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2018 results and corporate developments in
Oct 29, 2018
Summary ToggleIntellia Therapeutics Names Glenn Goddard as New Chief Financial Officer
CAMBRIDGE, Mass. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has named Glenn Goddard its executive vice president and chief
Oct 18, 2018
Summary ToggleIntellia Therapeutics Presents New Data in In Vivo and Ex Vivo Programs at the 26th Annual Congress of the European Society of Gene and Cell Therapy
Intellia scientists present first robust demonstration of CRISPR-mediated insertion of transgenes in the liver Non-human primate data show high correlation achieved between liver edit and reduction of TTR protein High rate and specificity of acute myeloid leukemia cell killing observed with
Sep 24, 2018
Summary ToggleIntellia Therapeutics to Present at October Healthcare Investor Conferences
CAMBRIDGE, Mass. , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will participate in the following upcoming healthcare conferences in October: Monday,
Sep 10, 2018
Summary ToggleCRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology
The interference proceeding remains terminated without any determination on inventorship of CRISPR/Cas9 genome editing application to eukaryotic cells University of California/University of Vienna /Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology
